Rocket Lab Corporation RKLB

Rocket Lab (RKLB) trades near $74 with a bull target around $119 and a BUY call from 24/7 Wall St., aided by a record backlog and rapid revenue growth. Q2 2026 revenue was $234 million, up 62% YoY, but GAAP EPS was -$0.08 amid $8.6 million in acquisition costs. Backlog rose to $2.36 billion, underpinning a vision to become a self-launching, tier-1 space player after completing Iridium, Mynaric, and Motiv deals. The key catalyst is Neutron, Rocket Lab’s medium-lift reusable rocket, targeting a Q4 2026 debut at $50–$55 million per flight, with bookings already secured as the NSSL market expands. Bulls see a path to about $155–$156 if Neutron flies cleanly and Iridium closes; bears warn on cash burn, ATM dilution, and execution risk. RKLB’s launch focus and backlog support a premium multiple versus peers. Neutron's debut and Iridium close could dramatically reshape RKLB's growth and valuation, though dilution and execution risk temper the upside.

Rocket Lab and Iridium won Iridium shareholders’ approval to be acquired, with 81% of outstanding shares voting in favor. The deal values Iridium at $54 per share (cash $27 plus Rocket Lab stock) and carries an enterprise value near $8 billion. It was first announced about two months ago and is expected to close by mid-next year, pending regulatory clearances. The merger would combine Rocket Lab’s launch and space-systems capabilities with Iridium’s global satellite network, potentially creating a differentiated LEO communications and services platform. Rocket Lab says it has secured non-stock financing for the deal, and both CEOs praised the vote as a step toward a stronger, innovative, global space business. The narrative also notes Iridium’s profitability and Starlink as competitive backdrop. Significant strategic move that could materially reshape RKLB’s scale and market position through the Iridium asset base and global network.

AST SpaceMobile (ASTS) trades around $62, with a price target of $89.40 implying about 44% upside. Bulls point to scale economics: six fully assembled satellites per month, 10 launches booked with two providers, and a goal of nearly $1B in revenue in the first year of commercial service, aided by a Rakuten/AST J-LEO deal worth up to $1B and a U.S. MNO joint venture. The bear case warns of dilution and delays: ASTS raised $1.15B in convertible notes, capex near $610M in Q2, and $118.8M in stock-based comp; any launch slump or MOUs stalling could push downside toward the $70s. Q2 revenue missed; GAAP EPS −$0.77 after a $125.9M loss tied to the BB7 launch. ASTS’s backlog sits at $1.30B, with ~45 Bluebird satellites planned by 2027. Iridium’s $8B Rocket Lab acquisition and Globalstar’s Amazon deal underscore D2D-market momentum. Iridium’s planned $8 billion acquisition of Rocket Lab signals sector consolidation that could affect RKLB’s prospects.

Rocket Lab launched its 97th Electron mission, its 18th in 2026, delivering Synspective's 13th StriX SAR satellite into a 559 km low Earth orbit from Launch Complex 1, New Zealand, named 'Owlright Owlright Owlright.' The 13th deployment completes another phase of the Synspective constellation with 100% mission success to date. The mission underscores Rocket Lab's reliable cadence for small-satellite deliveries, as 14 more Electron launches are planned to complete Synspective's SAR network by the end of the decade. Sustained high cadence and expanded backlog from a multi-year contract with Synspective strengthen RKLB's growth trajectory.

Rocket Lab trades at $73.61; Wall Street consensus price target $109.37 (~49% upside). New Street Research's Pierre Ferragu has a $150 12-month target, implying ~104% upside, citing Neutron commercialization at $50-55m per flight, expanding government wins (Space Force SB-AMTI $397m), and Iridium deal integration to scale. The stock peaked near $151; it fell >51% from that high amid Neutron delays (end-of-year launch window tightening; pad target Q4 2026 after stage-1 tank test failure) and dilution via ATM (~$1.08B raised; ~641M basic shares). Over 3 months RKLB down ~8.8%; 1Q-3Q 2026 results guidance and backlog; 18 analysts cover it: 3 Strong Buy, 11 Buy, 4 Hold. Intuitive Machines (LUNR) shows larger upside (88%), but RKLB is the only Western pure-play where a mainstream shop models a full double; bear risk includes execution and dilution; bull includes Iridium and Neutron milestones. Major catalysts (Neutron timeline, Iridium deal) and a high target implying a near-double could materially shift sentiment and valuation.

Iridium Communications stockholders approved Rocket Lab's plan to acquire Iridium in a $54-per-share deal, consisting of $27 in cash and Rocket Lab shares per Iridium share, with closing expected by mid-2027 and subject to regulatory approvals. About 99.6% of votes cast backed the merger, representing roughly 81% of outstanding shares. RKLB shares rose ~0.7% after hours; IRDM slipped ~0.29%. The transaction's notional value is $54 per Iridium share, with an exchange ratio collar. Rocket Lab CEO Peter Beck framed the merger as creating a 'space powerhouse' by combining Iridium's global network, spectrum, and operating experience with Rocket Lab's launch and space systems capabilities, potentially unlocking new space applications once closed. Retail sentiment on Stocktwits was bullish for IRDM and extremely bullish for RKLB, with high message volume. Combining Iridium's satellite network with Rocket Lab's launch and space tech could significantly expand addressable markets and long-term growth, though execution risk and regulatory approvals temper certainty.

Iridium Communications stockholders approved the Agreement and Plan of Merger with Rocket Lab in a special meeting, with about 99.6% of votes cast in favor, representing roughly 81% of outstanding common shares. Under the deal, Iridium shareholders will receive $27.00 in cash and a number of Rocket Lab common shares calculated by an exchange ratio, subject to a collar, for each Iridium share. The transaction carries a notional value of $54.00 per Iridium share and is expected to close by mid-2027, pending regulatory approvals and other customary closing conditions. The merger aims to combine Iridium's global satellite network and spectrum with Rocket Lab's launch and space systems capabilities to create a next-generation space powerhouse. The release contains forward-looking statements and various risk factors. Consolidation of Iridium's global network with Rocket Lab's launch capabilities could significantly alter market dynamics and investor sentiment.

ARK Invest added to Rocket Lab (RKLB) after Rocket Lab's Q2 2026 revenue rose 62% to $234.07 million and backlog reached a record $2.36 billion. ARK trimmed Alphabet (GOOGL/GOOG) positions but still held $118.5 million in GOOG and $27.0 million in GOOGL as of July 31, 2026. RKLB did not appear in ARK's ARKK snapshot at that date. Rocket Lab is rebuilding for growth: it plans to acquire Iridium Communications, financed partly by ATM proceeds of $1.53 billion in H1 2026, and is pursuing the Neutron medium-lift rocket for late-2026 launches. Valuation remains lofty (P/S around 58) with Q2 net income of -$49.3 million. Risks include equity dilution, Neutron timeline delays, and dependence on launches and large program awards. ARK's RKLB buying signals potential support and capital inflows, but the Iridium financing and Neutron delays introduce dilution and execution risk.

ARK Invest bought 359,612 more Rocket Lab shares worth about $25.1 million, adding to prior purchases and signaling continued bullish sentiment across ARK’s Innovation, Autonomous Tech & Robotics, and Space ETFs. Earlier in the month ARK bought an additional 200,303 RKLB shares for about $12.8 million. With SpaceX reportedly pausing new Falcon 9 rideshare sales and launch demand tightening, Rocket Lab could gain more customers if launch capacity remains constrained. Rocket Lab is preparing its 97th Electron launch on Sept. 25, carrying a StriX satellite for Synspective into low-Earth orbit, marking its fourth Electron launch in 25 days. The growth story also centers on Neutron, the planned larger rocket, and a possible Iridium acquisition. Cantor Fitzgerald’s Andres Sheppard has a $122 target; TipRanks cites 14 Buy and 3 Hold with an average $109.47 price target, with Electron launches and Neutron first flight as near-term catalysts. Persistent large ARK buying signals strong investor interest and potential upside from Neutron and strategic acquisitions.

ARK Invest, led by Cathie Wood, bought $25.13 million worth of Rocket Lab (RKLB) shares on Sept. 22 across ARK Innovation, ARKQ and ARKX ETFs, as RKLB trades around $70 after hitting a $151 high. The move follows Neutron launch delays, soft gross-margin guidance, and a costly $8 billion Iridium acquisition that introduces dilution and financing risk. Despite the setbacks, Wood has a history of deploying capital in beaten-down innovators when near-term fear intersects with a multi-year thesis. Rocket Lab's Q2 revenue rose 62% to $234 million, backlog is $2.36 billion, and Electron completed its 96th launch; Iridium expands global spectrum and subscriber base. ARK views Rocket Lab as a disruptive platform across launch, satellite manufacturing, defense and communications, though profitability and financing challenges remain. ARK's sizable, diversified buy signals long-term conviction and could buoy sentiment, but near-term execution, margin, and financing risks temper the impact.

Rocket Lab is positioning its Neutron rocket to fill a medium-lift gap as SpaceX winds down Falcon 9 later this decade, shifting focus to Starship for heavier payloads. Neutron targets a similar payload class to Falcon 9 and already carries a meaningful commercial and government backlog. The potential Falcon gap should not be the sole driver of investor interest; execution risks remain, including delays and elevated R&D spend. The piece notes two catalysts: Neutron's development timeline and any new signed contracts that add to backlog, plus customer signals shifting payloads away from Falcon-class missions. Watch Neutron launch dates and backlog evolution after 2028 as Falcon 9 availability eases. The narrative remains to see whether Neutron strengthens defense ties and margins, while underlying risks persist. Neutron could reallocate medium-lift demand away from Falcon-era capacity, potentially boosting RKLB backlog, margins, and defense contracts, but execution risks and timing keep upside from being uncertain.

Rocket Lab is pursuing an $8.1 billion deal to acquire Iridium Communications, financing it with a $1.9 billion share offering, a $1.7 billion amended Iridium term loan, existing liquidity, and previously secured debt. The merger would merge Rocket Lab’s rocket and satellite manufacturing with Iridium’s global satellite communications network, creating a fully integrated space operator offering rockets, satellites, and services. CEO Peter Beck has framed the move as a rebranding toward a 'tier-1 space power' and even suggested Space Lab as a better name, arguing that applications and services are the larger prize. Iridium brings recurring revenue and a large installed base; the deal is contingent on the Sept. 24 shareholder vote and regulatory approvals. The financing scale dwarfs Rocket Lab’s current size, raising integration risks and diluting existing shareholders, though Cantor Fitzgerald remains positive on the setup. Represents a transformative, high-impact pivot that could materially alter RKLB’s revenue mix and scale, potentially boosting long-term value but introducing execution risk.

Rocket Lab revenue $0.8B trailing twelve months; market cap $45.3B hints at big future upside if Neutron launches scale. Neutron, a larger rocket, has not flown yet; Electron, current rocket, has flown 96th mission by Sep 2026. Neutron priced at $50-55M per launch; demand high; Kepler Communications dedicated launch confirmed. Backlog around $2.36B end of Q2, with launch about 40% of that; management expects ~45.5% of total to convert within 12 months. Company remains unprofitable with LTM operating margin -29% but improving; Q2 cash burn $110M; liquidity ~ $2.4B. Management targets positive adjusted EBITDA after first Neutron launch and positive cash flow 1.5-2 years after. Key risk: execution; timing to deliver Neutron to pad by Q4 2026. Upside hinges on Neutron ramp and conversion of backlog. A successful Neutron program and faster backlog conversion could meaningfully alter profitability and drive upside in RKLB.

ARK Invest bought about 359,612 Rocket Lab shares across three ETFs for roughly $25.1 million, increasing its RKLB exposure while trimming Alphabet in Tuesday trades. The purchase comes after Rocket Lab completed a $1.944 billion share offering to help finance its planned Iridium acquisition, which is expected to close in mid-2027. Rocket Lab is also nearing the debut of its larger Neutron rocket and continues to expand beyond launch services, with the Iridium deal adding satellite communications operations and recurring revenue. ARK's moves do not disclose reasoning, but signal continued confidence in Rocket Lab's growth trajectory as the company pursues major milestones that could drive longer-term value, alongside a smaller reduction in Alphabet holdings. ARK's sizable stake and Iridium deal plus Neutron milestones could substantially shift RKLB's revenue mix and growth prospects.

ARK Invest bought 359,612 RKLB shares across ARKK, ARKQ and ARKX, about $25.7 million, its largest daily trade, signaling renewed confidence in Rocket Lab. Cantor Fitzgerald reiterated an overweight rating with a $122 target, citing Neutron and the $8 billion Iridium acquisition as major catalysts. SpaceX reportedly stopping new Falcon 9 rideshare sales could widen demand-supply gaps, potentially benefiting smaller launch players like RKLB, though Neutron still faces service-entry hurdles. Iridium would broaden Rocket Lab into satellite communications, with closing expected mid-2027. RKLB rose in pre-market trading and retail sentiment on Stocktwits remained bullish as the stock moved above the 50-day moving average. ARK's sizeable stake and Cantor's catalysts, plus SpaceX's strategic shift creating potential market opportunities, could meaningfully alter RKLB's growth trajectory.

StockStory highlights two large-cap buys—MercadoLibre (MELI) and Rocket Lab (RKLB)—and one to question, PepsiCo (PEP). PEP faces soft unit sales, an estimated 3.3% sales rise next year, and 5% EPS growth over three years, trading around $131.30 with a forward P/E near 14.9x. MELI is a LATAM online marketplace/fintech with 63.1% annual ARPU growth, 35% EPS growth over three years, a 33.4% free cash flow margin, and an 18.9x forward EV/EBITDA, at about $1,829. RKLB, valued at $43.08B, is described as the first private company in the Southern Hemisphere to reach space, with 53.4% revenue growth over two years, decreasing cash burn, improving ROIC, and a $72.01 share price trading with an extreme 3,106.2x forward P/E; readers are directed to a full free research report. Strong revenue growth and improving cash burn boost RKLB's long-term outlook, but extreme valuation risk tempers the potential upside.

Rocket Lab (RKLB) trades near a $40B market cap, about 50x trailing sales, implying a heavy growth premium. In Q2, revenue reached $234M, up 62% YoY; backlog rose to $2.36B, up 137%; more than $437M in new launch contracts were secured during the quarter and soon after. Electron remains core, but Rocket Lab is expanding into end-to-end space solutions—satellites, solar cells, flight software, and separation systems. Government contracting is increasing, including a July Space Force deal worth $266M for 12 suborbital launches with options for six more, and a $397M contract to build and launch spacecraft for the Space-Based Airborne Moving Target Indicator program. Neutron, a larger reusable rocket, targets constellation deployments and national-security missions; it carries execution risk. Balance sheet shows about $2.1B in cash plus $258M in marketable securities, keeping investment flexibility despite current unprofitability. A market crash could present a sizeable discount to capture growth and backlog. Huge backlog and cash reserves plus government contracts could sustain growth and attract buyers in a market crash.

Rocket Lab has gained about 1,600% in three years but now faces questions about whether the stock’s valuation matches its cash-generation potential. It recently completed a US$1.94 billion equity raise to fund the Iridium acquisition, reducing financing risk but boosting share count and diluting per-share future cash flows. Trailing free cash flow sits in a loss (about $370.5 million), while analysts expect a shift to positive cash flow later, contingent on the launch business and Iridium deal. At around $71.98 a share, investors are weighing a 12.3x price-to-book against a DCF-driven view that requires sizable later cash generation. The write-up also notes polar bull and bear narratives and flagging insider selling. Equity financing and the Iridium deal materially alter RKLB's capital structure and long-term cash-flow prospects, signaling a major strategic shift.

Rocket Lab CEO Peter Beck ties the proposed Iridium acquisition to a broader push into space-based communications, arguing spectrum—especially Iridium’s L-band—is the key prize as SpaceX and Amazon pursue their own spectrum bets. Beck says including Iridium would add satellite communications services and could lower deployment costs and timelines for new networks, potentially turning Rocket Lab into a 'Space Lab' that combines launch, spacecraft and services. In rough math, he estimates building and deploying Iridium’s constellation could cost about $350 million instead of $3 billion and take 12–24 months rather than more than five years. Iridium shareholders vote on Thursday; Rocket Lab has secured funding after a $1.944 billion share sale and expects the deal to close in mid-2027. The company is pursuing defense-oriented Space Force programs like SB-AMTI and Flatellite payloads, alongside broader commercial and national-security ambitions. Iridium spectrum assets and a full-stack space-communications platform could substantially alter RKLB's trajectory and competitive position.

Rocket Lab shares rose about 2% after news of fresh defense awards, satellite work, and financing progress tied to its planned Iridium acquisition. The company has secured $1.94 billion via an at-the-market share sale to fund Iridium, replacing a planned $3.6 billion bridge facility and diluting existing shareholders. Defense programs are boosting the order pipeline, including a $190 million award for 20 HASTE hypersonic test flights and a separate $266 million Space Force contract for at least 12 suborbital missions; Viasat also selected Rocket Lab to provide a satellite bus for a protected communications program. Rocket Lab has completed 96 Electron launches, with 17 so far this year. Raymond James initiated coverage with an $80 target, citing growth opportunities and a potential path toward positive EBITDA and free cash flow by 2027–2028, though the company remains loss-making with negative FCF. The financing reduces debt reliance but raises dilution. ATM funding and defense wins materially expand revenue pipeline and funding options, signaling significant potential upside despite ongoing losses.

SpaceX is winding down Falcon 9 as it shifts emphasis to Starship, potentially opening a major gap in launch capacity. Rocket Lab’s Neutron rocket could fill the void, with a target lift of ~13 metric tons to LEO and a backlog of more than 90 missions, including five dedicated Neutron flights. SpaceX paused selling new Falcon 9 slots beyond 2028; Starship is expected to absorb much of Falcon 9’s role, while competition from Blue Origin, Relativity Space, Stoke Space, and Firefly remains years away. Rocket Lab’s strategic moves include an $8 billion Iridium acquisition to create a satellite network, potentially guaranteeing Neutron launches. Even if Neutron debuts, it won’t instantly replace Falcon 9’s capacity. Winding down Falcon 9 could create a substantial near-term demand window for Neutron, benefiting RKLB's backlog and growth.

Wall Street is bullish on Rocket Lab (RKLB) with several analysts rating it a buy and a consensus target around $109, far above the roughly $64 share price. The latest quarterly results show a 62% year-over-year revenue gain and an exploding backlog exceeding $2.3 billion, signaling strong demand and momentum for the space company. Yet profitability remains distant, with operating expenses rising to $142 million in the quarter and $274 million year-to-date, and management warns cash burn will stay elevated for about two years after the Neutron rocket’s first flight. Launch timing for Neutron keeps slipping, now expected no earlier than 2027. The company is also integrating two recent acquisitions and preparing a deal with Iridium, increasing execution risk. With valuation near 50x sales, the stock trades at a premium that hinges on quick profits and flawless execution. Profits are not in sight yet, and delays plus acquisitions raise execution risk that could materially delay profitability and pressure the stock despite strong revenue growth.

Two space stocks are weighed: Redwire (RDW) and Rocket Lab (RKLB). RDW sells satellite components to civil, commercial, NASA, and the U.S. Space Force; FY2025 revenue about $335.4M (+10.3%), net loss around $226.6M (−67.6% margin). Debt/Equity ~0.12x, current ratio ~1.6x, free cash flow −$190.8M; revenue concentrated with two customers (~39% of 2025). RKLB pursues end-to-end space services, including launch vehicles; FY2025 revenue about $601.8M (+38%), net loss about −$198.2M (−32.9% margin). Current ratio ~4.1x, debt/Equity ~0.1x, free cash flow −$321.8M as it funds Neutron and long-term programs. Backlog surpassed $2B; RKLB pursuing Iridium acquisition financed by equity and loans; valuation is high relative to earnings; the case favors RKLB, though both remain unprofitable. Backlog exceeding $2B and major programs like Neutron, plus Iridium financing, could significantly shape RKLB's future.

Rocket Lab said it completed a $1.94 billion at-the-market stock sale to fund the cash portion of its $8 billion Iridium acquisition and terminated a $3.6 billion bridge loan. Roughly 29.3 million new shares were issued, diluting outstanding shares about 5% (4.5% including convertible preferreds). The sale price averaged around $66, below the current price and well under Iridium’s peak. The cash portion totals about $2.9 billion; the rest will come from existing cash, plus some of Iridium’s debt and fees. Abandoning the bridge loan avoids rapid refinancing into a high-rate environment for a money-losing company, though total share count could rise by as much as 12% when Iridium stock issued to sellers is factored in. Iridium reported about $872M revenue in 2025 and $495M OEBITDA; closing is targeted for mid-2027. Market cap sits above $40B, about 40x revenue. Equity dilution of up to about 5% now plus potential 12% total share count post-closing and a large cash-accretive acquisition create a material shift in RKLB's capital structure.

Rocket Lab Corporation (RKLB) closed at $71.98, up 2.99% after a day of mixed market action as the Dow fell 0.36% and the Nasdaq rose 0.45%. Over the past month, RKLB shares rose about 2.36%, outperforming the Aerospace sector, which fell roughly 8.1%, but lagging the S&P 500’s 1.27% gain. Investors await the next earnings release, with consensus for the upcoming quarter showing an EPS of -$0.02, a 300% decline from year-ago levels, while revenue is projected at $255.89 million, up 65% year over year. For the full year, Zacks Consensus calls for -$0.05 per share on revenue of $945.03 million, up about 81% and 57%, respectively. The piece notes recent estimate revisions and assigns RKLB a Zacks Rank of #2 (Buy); it also highlights the Aerospace-Defense Equipment industry’s rank within its sector. Forecasted loss with solid revenue growth could moderately influence sentiment and near-term stock dynamics.

Rocket Lab stock rose 2.2% to $71.45 after bouncing from support near $60 and breaking above its 50-day moving average, a move that previously rejected price in July and August. Schaeffer's analyst Rocky White notes the 50-day MA crossover has occurred eight times in the past decade; historically, the stock has risen about 88% of the time one month later, averaging a 16.8% gain, implying a potential move to roughly $83.45. The stock's current implied volatility is low (SVI around 70%, in the low 10th percentile), while a volatility scorecard shows the SVS at 97/100, indicating past outperformance vs. volatility expectations. Historical 50-day MA crossover events for RKLB have led to near-term gains about 88% of the time in the past decade.

Rocket Lab (RKLB) shows persistent revenue momentum and improving capital efficiency, but stock performance lags the market. Revenue grew at a 5-year CAGR of 68.9%, signaling strong demand for small-satellite launches. Free cash flow margin expanded by 59.4 percentage points over the period, though trailing-12-month FCF margin is negative at -48.3%, indicating near-term cash burn. ROIC has risen in recent years, suggesting improving returns on invested capital after COVID-era weakness. The stock trades around $71.89, up 5.7% over six months but well behind the S&P 500’s 16.2% gain. The piece notes a sky-high forward P/E of about 2,870x and invites readers to view a full free research report. Overall, the analysis points to Rocket Lab as a high-quality business with notable growth momentum, despite current cash flow and valuation caveats. Strong growth and improving ROIC could support upside, but persistent negative FCF and a sky-high forward P/E limit potential upside.

Rocket Lab plans to acquire Iridium Communications for about $6 billion in equity and $8.1 billion in enterprise value, financed through a $1.944 billion ATM equity offering, Iridium's amended $1.775 billion term loan, and Rocket Lab's liquidity. Iridium shareholders will receive $27 in cash plus a variable number of Rocket Lab shares, with an exchange ratio of 0.4 RKLB shares if the stock price is $67.50 or lower, and adjustments to keep the cash component near $27; closing is targeted mid-2027. Rocket Lab’s primary subsidiary will guarantee the debt; the bridge facility was terminated, reducing short-term risk but diluting existing shareholders via the ATM. The company says Iridium adds an established comms network and recurring services, enabling a fully integrated, self-launching, tier-1 space power spanning rockets, satellites, and services. Cantor Fitzgerald reiterates overweight with a $122 target; Neutron’s first launch and Iridium close are catalysts. RKLB rose on the news. Transforms RKLB into an integrated space services provider with growth catalysts, though financing/dilution and execution risk temper returns.

Rocket Lab shares rose about 8.2% after Cantor Fitzgerald reiterated an Overweight rating and a $122 target, highlighting upcoming catalysts: the maiden Neutron rocket launch and the Iridium acquisition completion. Cantor cites Rocket Lab's execution after its 96th Electron mission, its dedicated launch pads, diverse customer base, expanding rocket portfolio, and proven launch track record as competitive advantages. The firm argues the price target implies ~89% upside. Two major catalysts could materially alter growth trajectory: Neutron maiden flight and Iridium closing. The move follows strong Q1 2026 results where revenue rose 63.5% to $200.3 million, with guidance for Q2 around $232.5 million and positive adjusted EBITDA of $23 million. Year-to-date the stock is down about 8%, trading well below its 52-week high. Two major catalysts could materially alter Rocket Lab's growth trajectory and investor sentiment.

Rocket Lab's stock rose after Cantor Fitzgerald analyst Andres Sheppard reiterated an Outperform rating with a $122 price target, boosting shares amid a broader rally in the space sector. The note frames Rocket Lab as increasingly competitive with SpaceX and signals ongoing growth in the market for space services and launches. Analyst upgrade and bullish target could moderately improve near-term sentiment and stock performance without guaranteeing sustained gains.